Skip to content
The Nexus
DossierENTITY

Primary immunoglobulin A nephropathy

Coverage of Primary immunoglobulin A nephropathy in the Nexus archive.

Earliest in view: Jul 17 · 17:47 UTCMost recent: Jul 17 · 17:47 UTC
Co-mentioned in this coverage
Novartisorganization1FDAorganization1Iptacopantopic1Fabhaltatopic1
Recent coverage
  • HEALTHJul 17 · 17:47 UTCMEDPAGE TODAY
    First Complement Inhibitor Wins Full Approval in IgA Nephropathy

    The FDA fully approved iptacopan (Fabhalta), a complement inhibitor, to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of progression. Novartis announced the approval, marking the first complement inhibitor approved for this condition.

Primary immunoglobulin A nephropathy · Dossier · The Nexus